92 related articles for article (PubMed ID: 20515689)
21. Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci.
Frosi Y; Inoue K; Ramlan SR; Lane DP; Watanabe T; Brown CJ
Sci Rep; 2019 Nov; 9(1):17933. PubMed ID: 31784573
[TBL] [Abstract][Full Text] [Related]
22. Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development.
Steinman HA; Hoover KM; Keeler ML; Sands AT; Jones SN
Oncogene; 2005 Nov; 24(53):7935-40. PubMed ID: 16027727
[TBL] [Abstract][Full Text] [Related]
23. MDM2-MDM4 molecular interaction investigated by atomic force spectroscopy and surface plasmon resonance.
Moscetti I; Teveroni E; Moretti F; Bizzarri AR; Cannistraro S
Int J Nanomedicine; 2016; 11():4221-9. PubMed ID: 27621617
[TBL] [Abstract][Full Text] [Related]
24. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
[TBL] [Abstract][Full Text] [Related]
25. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice.
Iwakuma T; Parant JM; Fasulo M; Zwart E; Jacks T; de Vries A; Lozano G
Oncogene; 2004 Oct; 23(46):7644-50. PubMed ID: 15361844
[TBL] [Abstract][Full Text] [Related]
26. Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death.
Boesten LS; Zadelaar SM; De Clercq S; Francoz S; van Nieuwkoop A; Biessen EA; Hofmann F; Feil S; Feil R; Jochemsen AG; Zurcher C; Havekes LM; van Vlijmen BJ; Marine JC
Cell Death Differ; 2006 Dec; 13(12):2089-98. PubMed ID: 16729027
[TBL] [Abstract][Full Text] [Related]
27. Binding induced folding in p53-MDM2 complex.
Chen HF; Luo R
J Am Chem Soc; 2007 Mar; 129(10):2930-7. PubMed ID: 17302414
[TBL] [Abstract][Full Text] [Related]
28. Fragment-based library generation for the discovery of a peptidomimetic p53-Mdm4 inhibitor.
Boltjes A; Huang Y; van de Velde R; Rijkee L; Wolf S; Gaugler J; Lesniak K; Guzik K; Holak TA; Dömling A
ACS Comb Sci; 2014 Aug; 16(8):393-6. PubMed ID: 24983416
[TBL] [Abstract][Full Text] [Related]
29. Reactivation of p53: from peptides to small molecules.
Brown CJ; Cheok CF; Verma CS; Lane DP
Trends Pharmacol Sci; 2011 Jan; 32(1):53-62. PubMed ID: 21145600
[TBL] [Abstract][Full Text] [Related]
30. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
Dezi C; Carotti A; Magnani M; Baroni M; Padova A; Cruciani G; Macchiarulo A; Pellicciari R
J Chem Inf Model; 2010 Aug; 50(8):1451-65. PubMed ID: 20726601
[TBL] [Abstract][Full Text] [Related]
31. Structure of human MDM4 N-terminal domain bound to a single-domain antibody.
Yu GW; Vaysburd M; Allen MD; Settanni G; Fersht AR
J Mol Biol; 2009 Feb; 385(5):1578-89. PubMed ID: 19084022
[TBL] [Abstract][Full Text] [Related]
32. Dual-site regulation of MDM2 E3-ubiquitin ligase activity.
Wallace M; Worrall E; Pettersson S; Hupp TR; Ball KL
Mol Cell; 2006 Jul; 23(2):251-63. PubMed ID: 16857591
[TBL] [Abstract][Full Text] [Related]
33. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.
Chandler DS; Singh RK; Caldwell LC; Bitler JL; Lozano G
Cancer Res; 2006 Oct; 66(19):9502-8. PubMed ID: 17018606
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel mdm2 binding peptides by phage display.
Böttger V; Böttger A; Howard SF; Picksley SM; Chène P; Garcia-Echeverria C; Hochkeppel HK; Lane DP
Oncogene; 1996 Nov; 13(10):2141-7. PubMed ID: 8950981
[TBL] [Abstract][Full Text] [Related]
35. Interaction of p53 with Mdm2 and azurin as studied by atomic force spectroscopy.
Funari G; Domenici F; Nardinocchi L; Puca R; D'Orazi G; Bizzarri AR; Cannistraro S
J Mol Recognit; 2010; 23(4):343-51. PubMed ID: 19941302
[TBL] [Abstract][Full Text] [Related]
36. Knowledge-based virtual screening: application to the MDM4/p53 protein-protein interaction.
Jacoby E; Boettcher A; Mayr LM; Brown N; Jenkins JL; Kallen J; Engeloch C; Schopfer U; Furet P; Masuya K; Lisztwan J
Methods Mol Biol; 2009; 575():173-94. PubMed ID: 19727615
[TBL] [Abstract][Full Text] [Related]
37. Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition.
Macchiarulo A; Giacchè N; Carotti A; Baroni M; Cruciani G; Pellicciari R
J Chem Inf Model; 2008 Oct; 48(10):1999-2009. PubMed ID: 18826207
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.
Lu Y; Nikolovska-Coleska Z; Fang X; Gao W; Shangary S; Qiu S; Qin D; Wang S
J Med Chem; 2006 Jun; 49(13):3759-62. PubMed ID: 16789731
[TBL] [Abstract][Full Text] [Related]
39. G alpha 12/13 basally regulates p53 through Mdm4 expression.
Kim MS; Lee SM; Kim WD; Ki SH; Moon A; Lee CH; Kim SG
Mol Cancer Res; 2007 May; 5(5):473-84. PubMed ID: 17510313
[TBL] [Abstract][Full Text] [Related]
40. Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations.
Espinoza-Fonseca LM; Trujillo-Ferrara JG
Biopolymers; 2006 Nov; 83(4):365-73. PubMed ID: 16817233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]